Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Lab Notes: Proscia AI advancement

Proscia
By Author Proscia | October 8, 2021

The Philadelphia digital and computational pathology services provider released study results on the company’s technology that leverages artificial intelligence to automatically detect melanoma with a high degree of accuracy.

Melanoma is the most deadly type of skin cancer. Health officials estimate about 106,000 adults in the United States will be diagnosed with invasive melanoma of the skin thus year.

Proscia’s prospective study, conducted at Thomas Jefferson University and the University of Florida, demonstrated the real-world performance of its AI technology on an uncurated set of 1,422 sequential skin biopsies. The technology correctly identified invasive melanoma and melanoma in situ with a sensitivity of 93% and a specificity of 91%.

Our website uses cookies. By using this site, you agree to its use of cookies.